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Abstract
Background: With regard to switching tumor necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA),
conflicting results have been reported as to whether the effectiveness of a second TNFi depends on the reason for
discontinuation of the first TNFi.
Methods: Patients with a clinical diagnosis of axSpA starting a second TNFi in the Swiss Clinical Quality Management
cohort were included. Effectiveness of treatment at 1 year, as well as drug survival, was compared between subgroups
having discontinued the first TNFi because of lack of response, adverse events (AEs), or other reasons. Lack of response
was further divided into primary or secondary lack of response (PLR or SLR, respectively), depending on whether the
first TNFi was stopped before or after 6 months of treatment.
Results: Among 632 patients with axSpA, median survival of a second TNFi was 1.1 years after PLR and 3.8 years after
SLR (p = 0.003). At least moderate disease activity as defined by an Ankylosing Spondylitis Disease Activity Score using
the erythrocyte sedimentation rate (ASDAS-ESR) <2.1 was achieved after 12 months by 11 %, 39 %, 26 %, and 39 % of
patients who discontinued their first TNFi because of PLR, SLR, AEs, and other reasons, respectively (p = 0.01). Only 4 %
of patients achieved an ASDAS-ESR inactive disease state after PLR, in comparison to 22 % of those after SLR. Similar
results were demonstrated in patients fulfilling the Assessment of SpondyloArthritis international Society classification
criteria for axSpA (n = 488): ASDAS-ESR <2.1 was achieved after 12 months by 9 %, 41 %, 29 %, and 39 % of patients
who discontinued their first TNFi because of PLR, SLR, AEs, and other reasons, respectively (p = 0.01).
Conclusions: The effectiveness of a second TNFi is significantly impaired in patients with axSpA after PLR to a first TNFi
compared with SLR.
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Background
Although the use of tumor necrosis factor-α inhibitors
(TNFi) has revolutionized the treatment of axial spondy-
loarthritis (axSpA), a significant proportion of patients do
not adequately respond [1–5]. Young age, male sex, high
baseline Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI), low baseline Bath Ankylosing Spondylitis
Functional Index (BASFI), high baseline C-reactive protein
(CRP), human leukocyte antigen B27 (HLA-B27) positiv-
ity, and the absence of enthesitis have been described as
predictors of good response to TNFi [6, 7]. We addition-
ally identified smoking to be associated with a worse out-
come following TNFi treatment in patients with axSpA
[8]. Switching to an alternative TNFi appears to be associ-
ated with lower response and/or drug survival rates in pa-
tients with ankylosing spondylitis (AS) [9–24]. In patients
with rheumatoid arthritis (RA), response to a second TNFi
seemed better if the first TNFi was discontinued because
of loss of efficacy or adverse events (AEs) in comparison to
a primary lack of efficacy [25, 26]. So far, no evidence for a
differential response to a second TNFi in dependence on
the reason for discontinuation of the first TNFi has been
observed in axSpA. As new compounds with different
modes of action are currently being tested in axSpA as po-
tential alternatives to TNFi switching [27–29], we explored
the effectiveness of switching TNFi in a large real-life ob-
servational axSpA cohort.
Methods
Study population
We conducted a longitudinal analysis of data collected
annually from patients with a clinical diagnosis of
axSpA, including AS, recruited in the ongoing Swiss
Clinical Quality Management (SCQM) Cohort from
January 2005 to September 2015 [30]. Clinical assess-
ments included a physical examination (spinal and hip
mobility according to the Bath Ankylosing Spondylitis
Metrology Index, measurement of height and weight,
presence of peripheral arthritis, dactylitis as well as
enthesitis), laboratory tests (erythrocyte sedimentation
rate [ESR] and CRP levels), data on treatment with non-
steroidal anti-inflammatory drugs (NSAIDs) as present
or absent, and data on conventional and biologic
disease-modifying drugs with dosage and start and stop
dates [31]. The following reasons for drug discontinu-
ation were specified in the database by the treating
rheumatologist: insufficient effectiveness, AEs, remis-
sion, and other reasons. There was no further specifica-
tion of the “other reasons” category of discontinuation
in the SCQM questionnaire, but these reasons may be
manifold, such as personal preference by the patient or
physician, pregnancy, or elective surgery. As discontinu-
ation due to remission was observed in only 1.9 % of the
patients, we pooled this category together with the
“other reasons” category for discontinuation. Patient
questionnaires included the BASDAI, the BASFI, smok-
ing status (never, previous, or current), and the number
of weekly exercise sessions.
Inclusion criteria for the present study
Patients with a clinical diagnosis of axSpA who had initi-
ated a second TNFi after recruitment into the SCQM-
axSpA cohort were included. Interruptions of treatment
with the same TNFi were not counted as switches.
Patients with overlapping TNFi courses or with an
unclear start date were excluded. The study was approved
by the ethics commission of the Canton of Zurich.
Written informed consent was obtained from all patients.
Outcomes
The primary outcome was drug survival of a second
TNFi in relation to the reason for discontinuation of the
first TNFi. In the case of several reasons for drug dis-
continuation, the following hierarchy was implemented:
lack of effect > AE > other reasons. Only the discontinu-
ation reason highest in hierarchy was used. Lack of effi-
cacy was further divided into primary lack of response
(PLR) if the first TNFi was stopped within 6 months
after start and in secondary lack of response (SLR) if the
first TNFi was discontinued after a 6-month period. The
Assessment of SpondyloArthritis international Society
(ASAS) recommends assessment of response to treat-
ment after at least 12 weeks [32]. We chose a cutoff of
6 months, however, as clinically relevant improvement
may take longer than 3 months [33, 34]. Moreover, the
treating rheumatologist has to apply for reimbursement for
an alternative TNFi in Switzerland, which may delay the
switching process for a couple of weeks. The co–primary
outcome of interest was effectiveness of treatment,
assessed as the proportion of patients reaching at least an
Ankylosing Spondylitis Disease Activity Score (ASDAS)
moderate disease activity state (ASDAS <2.1), an ASDAS
inactive disease state (ASDAS <1.3), or the ASAS criteria
for partial remission (ASAS-PR) at 12 ± 3 months [35, 36].
Achievement of ASDAS cutoffs is primarily presented
using the ESR, as CRP levels are registered in SCQM
Cohort with the respective reference level and not the
detection level, thus impeding the recently proposed
ASDAS-CRP imputation [37] in some patients. Re-
sults derived using ASDAS-CRP are presented in (see
Additional file 2: Table S2) after assuming a constant
number of 2 for CRP levels <2. Response was
assessed in patients with available outcome values at
12 months. Patients with available outcome measures
at this time point who had discontinued the first
TNFi but had not started an alternative TNFi were
considered nonresponders (response/tolerance ana-
lysis). Additionally, response was assessed only among
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patients still on treatment at 12 ± 3 months (per-
protocol response analysis).
Statistical analysis
Baseline characteristics in terms of categorical variables
were compared between patients starting a second TNFi
after different reasons for discontinuation of the first
TNFi using the χ2 test. For symmetrically distributed
discrete or continuous variables, analysis of variance was
used for testing whether the means in the different
groups were equal. The Kruskal-Wallis test was used for
data with skewed distribution. All tests were two-sided,
with the significance level set at 0.05.
Drug maintenance was described with Kaplan-Meier
plots. The log-rank test was used for testing differences
between groups shown in the plots. Multiple adjusted Cox
proportional hazards models were set up to estimate a
covariate-adjusted effect of the reason for discontinuation
of the first TNFi on the drug maintenance of the second
TNFi. Ongoing treatments were censored at the last visit
in the cohort. The following covariates were used: sex,
age, calendar year of switch (to account for the number of
various anti-TNF agents available for switch), the
individual anti-TNF agents, and the type of TNFi switch
(monoclonal antibody [mAb] to mAb versus mAb to
soluble receptor anti-TNF agent and vice versa). To assess
the significance of differences in response rates after 1 year
of treatment with the second TNFi, Fisher’s exact test was
used. R statistical software was used for all analyses.
Results
Patient disposition and baseline characteristics
A total of 686 patients with axSpA started treatment
with a second TNFi after inclusion in the SCQM
Cohort. A total of 54 patients lost to follow-up after the
start of a second TNFi were excluded from the analyses.
The baseline characteristics at the start of the second
TNFi in these patients, stratified by the reason of dis-
continuation of the first TNFi (PLR in 23.1 %, SLR in
42.7 %, AEs in 19.8 %, other in 14.4 %), are shown in
Table 1. There was an enrichment of patients with
predictors of an impaired response to TNFi in the group
having stopped the first TNFi because of PLR: higher pro-
portion of HLA-B27 negativity and presence of enthesitis,
higher BASFI, and higher proportions of smokers and of
patients classified as having nonresponsive axSpA. Pa-
tients in the PLR group also displayed higher baseline
BASDAI and ASDAS levels, and a higher percentage were
treated with NSAIDs. A similar enrichment of patients
with predictors of an unfavorable response, as well as of
patients with a higher disease activity, was found in pa-
tients who met the ASAS classification criteria for axSpA
(n = 488) (Table 2). The proportion of patients stopping
their first TNFi because of PLR was similar in the groups
Table 1 Characteristics of patients with a clinical diagnosis of axial spondyloarthritis starting a second tumor necrosis factor inhibitor
Parameter Number of patients PLR (n = 146) SLR (n = 270) AE (n = 125) Other (n = 91) p Value
Male sex, % 632 47.3 56.3 46.4 52.8 0.20
Age, years 632 43.8 ± 10.5 44.4 ± 11.1 44.1 ± 12.3 45.0 ± 13.1 0.87
Radiographic axSpA, % 454 54.4 69.2 65.8 82.1 0.003
HLA-B27–positive, % 510 43.2 67.1 64.3 71.0 <0.001
Elevated CRP, % 361 30.4 34.2 42.7 29.2 0.33
ASDAS-CRP 316 3.4 ± 0.8 3.1 ± 0.9 3.0 ± 1.1 2.7 ± 1.0 <0.001
ASDAS-ESR 289 3.1 ± 0.8 2.8 ± 0.8 2.8 ± 1.2 2.6 ± 1.2 0.03
BASDAI 348 6.0 ± 1.8 5.2 ± 2.0 4.9 ± 2.3 4.5 ± 2.3 <0.001
BASFI 345 4.6 ± 2.5 4.1 ± 2.5 3.7 ± 2.5 2.8 ± 2.3 0.001
BASMI 288 2.1 ± 1.9 2.3 ± 2.0 2.4 ± 2.1 2.7 ± 1.9 0.36
Peripheral arthritis, % 629 41.4 37.0 31.7 30.8 0.26
Enthesitis heel, % 632 42.5 31.9 26.4 24.2 0.01
Smokers, % 602 67.6 57.2 69.0 50.0 0.01
DMARDs, % 632 21.2 24.1 12.0 24.2 0.03
NSAIDs, % 632 62.3 54.4 48.0 39.6 0.003
BMI, kg/m2 608 26.3 ± 4.9 25.6 ± 4.9 25.9 ± 4.7 25.7 ± 4.7 0.58
Years of education 596 13.0 ± 3.0 13.5 ± 3.0 13.3 ± 2.9 14.1 ± 3.2 0.07
axSpA axial spondyloarthritis, ASAS Assessment of SpondyloArthritis international Society, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score using C-reactive
protein, ASDAS-ESR Ankylosing Spondylitis Disease Activity Score using erythrocyte sedimentation rate, BASDAI Bath Ankylosing Spondylitis Disease Activity Index,
BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, DMARDs disease-modifying antirheumatic drugs,
NSAIDs nonsteroidal anti-inflammatory drugs, BMI body mass index
Except where indicated otherwise, values for continuous variables are mean (±SD)
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with a clinical diagnosis of axSpA, those fulfilling the
ASAS criteria, and those who met the modified New York
criteria (23.1 %, 22.5 %, and 20.0 %, respectively). A similar
proportion of TNFi-treated patients in the PLR and SLR
groups was concurrently treated with conventional
disease-modifying antirheumatic drugs (Tables 1 and 2).
Drug retention
The median drug retention of the second TNFi was
2.29 years (95 % confidence interval [CI] 1.79–2.97) for all
patients with axSpA and 2.61 years (95 % CI 2.05–3.28) in
the subgroup fulfilling the ASAS axSpA classification cri-
teria. Drug maintenance depending on the reason for dis-
continuation of the first TNFi is shown in Fig. 1 for all
patients with a clinical diagnosis of axSpA and in Fig. 2
for patients fulfilling the ASAS axSpA classification cri-
teria. Significant differences in retention rates were found
between the four groups (p = 0.001), with the shortest
drug survival observed after previous PLR. The median
drug survival of a second TNFi was 1.06 years (95 % CI
0.75–1.96) after PLR and 3.76 years (95 % CI 3.12–4.28)
after SLR (p = 0.003). This difference remained significant
after adjustment for sex, age, the calendar year of switch-
ing (reflecting the number of available TNFi at each time
point), and the type of TNFi switching (mAb to mAb ver-
sus mAb to fusion protein anti-TNF agent and vice versa)
Table 2 Characteristics of patients fulfilling the ASAS axial spondyloarthritis classification criteria starting a second tumor necrosis
factor inhibitor
Parameter Number of patients PLR (n = 110) SLR (n = 220) AE (n = 88) Other (n = 70) p Value
Male sex, % 488 47.3 60.9 53.4 55.7 0.12
Age, years 488 42.8 ± 10.2 43.2 ± 10.9 42.3 ± 11.8 44.2 ± 13.4 0.77
Radiographic axSpA, % 388 66.7 77.4 82.5 87.9 0.02
HLA-B27–positive, % 442 51.6 73.7 75.0 78.3 <0.001
Elevated CRP, % 285 34.8 37.0 52.0 30.8 0.15
ASDAS-CRP 256 3.4 ± 0.9 3.1 ± 0.9 3.0 ± 1.2 2.7 ± 1.1 0.003
ASDAS-ESR 233 3.2 ± 0.8 2.8 ± 0.8 2.8 ± 1.2 2.7 ± 1.2 0.08
BASDAI 275 6.1 ± 1.9 5.1 ± 2.0 4.7 ± 2.4 4.6 ± 2.3 <0.001
BASFI 274 4.7 ± 2.5 4.1 ± 2.5 3.5 ± 2.4 3.0 ± 2.2 0.002
BASMI 228 2.1 ± 1.7 2.3 ± 2.0 2.7 ± 2.3 2.9 ± 2.0 0.27
Peripheral arthritis, % 487 36.7 35.5 26.1 21.4 0.06
Enthesitis heel, % 488 40.0 33.2 26.1 22.9 0.06
Smokers, % 471 73.4 58.4 72.3 55.7 0.01
DMARDs, % 488 20.0 22.7 9.1 17.1 0.03
NSAIDs, % 488 62.7 54.5 50.0 35.7 0.01
BMI, kg/m2 478 26.1 ± 4.6 25.7 ± 4.8 26.0 ± 4.7 26.2 ± 4.8 0.88
Years of education 463 13.0 ± 3.2 13.5 ± 3.0 13.0 ± 2.9 13.9 ± 3.2 0.23
axSpA axial spondyloarthritis, ASAS Assessment of SpondyloArthritis international Society, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score using C-reactive
protein, ASDAS-ESR Ankylosing Spondylitis Disease Activity Score using erythrocyte sedimentation rate, BASDAI Bath Ankylosing Spondylitis Disease Activity Index,
BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, DMARDs disease-modifying antirheumatic drugs,
NSAIDs nonsteroidal anti-inflammatory drugs, BMI body mass index
Except where indicated otherwise, values for continuous variables are mean (±SD)
Fig. 1 Drug survival of the second tumor necrosis factor inhibitor
(TNFi), stratified by the reason for discontinuation of the first TNFi, in
patients with a clinical diagnosis of axial spondyloarthritis. Other refers
to reason for discontinuation other than lack of effect or intolerance.
AE adverse events, PLR primary lack of response, SLR secondary lack
of response
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(Table 3). The hazard ratio for discontinuing the second
TNFi after previous SLR in comparison to PLR was 0.56
(95 % CI 0.42–0.75, p < 0.001) in all patients diagnosed as
having axSpA and 0.58 (95 % CI 0.42–0.81, p = 0.002) in
those patients fulfilling the ASAS axSpA classification cri-
teria. Similar results were found after replacing the type of
TNFi switching by the various anti-TNF agents in the
model (adalimumab, certolizumab, etanercept, golimu-
mab, infliximab).
Clinical response
Response to treatment with a second TNFi was
assessed in patients with available outcome values at
12 ± 3 months (ASAS-PR [n = 227, 36 %] and ASDAS-
ESR [n = 184, 29 %]). Patients with versus without
follow-up at this time point did not differ with regard
to important baseline disease characteristics (BASDAI,
ASDAS, elevated CRP, HLA-B27, classification as AS,
age, peripheral arthritis, enthesitis, smoking, educa-
tion, reason for discontinuation of first TNFi, physical
exercise, body mass index) (see Additional file 1:
Table S1).
Response rates to a second TNFi differed significantly
between the subgroups, based on the reasons for discon-
tinuation of the first TNFi (Table 4). These were most im-
paired in the subgroup of patients having discontinued the
first TNFi as a consequence of PLR, followed by AEs.
At least moderate disease activity (defined by
ASDAS-ESR <2.1) was reached by 11 %, 26 %, and 39 %
of patients in the PLR, AE, and SLR groups, respectively.
Only a negligible proportion of patients achieved ASAS-
PR or ASDAS-ESR inactive disease state after PLR (2 %
and 4 % of patients, respectively), as opposed to 13 % and
22 %, respectively, after SLR. Similar results were found in
patients fulfilling the ASAS axSpA classification criteria
(Table 4) and when using the CRP for ASDAS calculation
(see Additional file 2: Table S2).
Discussion
Our TNFi switching study in axSpA, which to our
knowledge is the largest so far, suggests that the reason
for discontinuation of a first TNFi may affect the effect-
iveness of a second TNFi, as previously reported in RA
[25, 26]. Drug retention and treatment responses after
switching to a second TNFi in axSpA were impaired in
patients having discontinued the first TNFi due to pri-
mary lack of effectiveness in comparison to SLR. Earlier
investigations had been hampered by the fact that it was
often not possible to distinguish between these two rea-
sons for drug discontinuation [18, 22]. As ASAS
Fig. 2 Drug survival of the second tumor necrosis factor inhibitor
(TNFi), stratified by the reason for discontinuation of the first TNFi, in
patients fulfilling the Assessment of SpondyloArthritis international
Society axial spondyloarthritis classification criteria. Other refers to
reason for discontinuation other than lack of effect or intolerance.
AE adverse events, PLR primary lack of response, SLR secondary lack
of response
Table 3 Cox models for drug retention of a second tumor necrosis factor inhibitor in patients having discontinued the first tumor
necrosis factor inhibitor due to primary or secondary lack of response
Patients with a clinical diagnosis of axSpAa Patients fulfilling the ASAS axSpA classification criteriab
HR 95 % CI p Value HR 95 % CI p Value
SLR vs. PLR 0.56 0.42–0.75 <0.001 0.58 0.42–0.81 0.002
Female vs. male 0.94 0.71–1.24 0.65 0.90 0.64–1.25 0.53
Age 1.00 0.99–1.02 0.73 1.00 0.99–1.02 0.93
Cept→mAbc 1.11 0.79–1.55 0.56 1.17 0.78–1.73 0.45
mAb→ Ceptc 1.11 0.80–1.56 0.54 1.24 0.84–1.82 0.28
2007–2010 vs. before 2006 1.26 0.50–3.12 0.63 1.18 0.47–2.96 0.73
2010–2015 vs. before 2006 1.58 0.63–3.99 0.33 1.44 0.57–3.67 0.44
ASAS Assessment of SpondyloArthritis international Society, axSpA axial spondyloarthritis, Cept soluble receptor anti–tumor necrosis factor agent, mAb monoclonal
antibody anti–tumor necrosis factor agent, HR hazard ratio, CI confidence Interval, PLR primary lack of response, SLR secondary lack of response
aTotal of 416 patients and 207 discontinuation events
bTotal of 330 patients and 157 discontinuation events
cIndicated switch type versus reference category mAb→mAb
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recommends assessment of treatment response after at
least 12 weeks [32] but time to improvement may be
longer than 3 months [33, 34], we have defined a discon-
tinuation due to an insufficient effect after 6 months of
treatment as being the consequence of a loss of efficacy.
This cutoff allowed us to evaluate drug retention and re-
sponse rates of the second TNFi. We found a difference
of 2.7 years in median retention of the second TNFi be-
tween patients in the PLR and SLR groups. Moreover, an
ASDAS-ESR inactive disease state was reached by only
4 % of patients after previous PLR in comparison to
22 % after SLR. Thus, PLR may identify a subgroup of
patients in whom TNF probably does not play a major
role in disease pathogenesis and amplification of inflam-
mation. Whether these patients would experience a
superior response to biologics with a different mode of ac-
tion, as demonstrated for RA [38], remains to be estab-
lished. An alternative, though mutually not exclusive,
reason for impaired effectiveness of the second TNFi in
the PLR group is a higher proportion of patients with pre-
dictors of an impaired response to anti-TNF agents [7] in
our study (normal CRP, HLA-B27 negativity, high BASFI
levels, and frequent enthesitis). Furthermore, misdiagnosis
in some patients in the PLR group cannot be ruled out in
the PLR group, given the low percentage of HLA-B27–
positive patients (43 %). We expected a lower proportion
of PLR patients in the groups fulfilling the ASAS classifi-
cation criteria or the modified New York classification
criteria, which was not the case, however. Finally, even
with a correct diagnosis of axSpA, patients may have
additional reasons for back pain (e.g., degenerative spinal
disease or fibromyalgia [39–41]), which may be misinter-
preted as axSpA activity, prompting the initiation of anti-
TNF treatment. Reassessment of a diagnosis of axSpA and
of musculoskeletal comorbidities in patients having expe-
rienced PLR to a first TNFi seems advisable before initiat-
ing a next biologic.
The results were very similar in patients with a clinical
diagnosis of axSpA made by their treating rheumatolo-
gist and those fulfilling the ASAS classification criteria
for axSpA. The presentation of patients with axSpA
diagnosed on clinical grounds also allows comparison
with TNFi switching in other observational cohorts
[18, 22], where the proportion of patients fulfilling the
modified New York criteria or the ASAS axSpA classifica-
tion criteria was not reported. The median drug survival
of a second TNFi was 2.3 years in SCQM and 1.6 years in
the Danish DANBIO registry [22]. In DANBIO, the
proportion of patients with a clinical diagnosis of AS
treated for at least 2 years with a second TNFi who
reached an ASDAS-CRP <2.1 was 37 %. We found a simi-
lar proportion of patients with axSpA (43 %) with an
ASDAS-ESR <2.1 at 1 year of treatment with a second
TNFi. Our result differed significantly in dependence on
the reason for discontinuation of the first TNFi: only 22 %
after previous PLR, 36 % after AEs and 51 % after SLR.
Table 4 Response rates after 1 year of treatment with a second tumor necrosis factor inhibitor, stratified by the reason of
discontinuation of the first tumor necrosis factor inhibitor
Response criterion Analysis Number of patients All PLR SLR AE Other p Valuea p Valueb
Patients with a clinical diagnosis of axSpA
ASDAS-ESR <2.1 Response/tolerance 184 28.8 11.1 38.9 26.2 38.9 0.01 0.002
ASDAS-ESR <2.1 Per protocol 124 42.7 21.7 50.8 35.5 63.6 0.04 0.02
ASDAS-ESR <1.3 Response/tolerance 184 14.7 4.4 21.5 9.5 22.2 0.03 0.01
ASDAS-ESR <1.3 Per protocol 124 21.8 8.7 28.8 12.9 36.4 0.07 0.08
ASAS-PR Response/tolerance 227 11.0 2.0 12.5 13.7 16.7 0.08 0.04
ASAS-PR Per protocol 146 17.1 4.2 17.4 18.4 33.3 0.12 0.17
Patients fulfilling the ASAS axSpA classification
ASDAS-ESR <2.1 Response/tolerance 148 31.1 9.1 40.9 29.0 38.9 0.01 0.001
ASDAS-ESR <2.1 Per protocol 100 46.0 18.8 55.1 37.5 63.6 0.04 0.02
ASDAS-ESR <1.3 Response/tolerance 148 16.2 3.0 22.7 12.9 22.2 0.045 0.02
ASDAS-ESR <1.3 Per protocol 100 24.4 6.2 30.6 16.7 36.4 0.13 0.09
ASAS-PR Response/tolerance 179 11.7 0.0 12.5 16.7 18.5 0.03 0.03
ASAS-PR Per protocol 106 18.1 0.0 17.5 21.4 35.7 0.05 0.10
axSpA axial spondyloarthritis, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score using C-reactive protein, ASDAS-ESR Ankylosing Spondylitis Disease Activity
Score using erythrocyte sedimentation rate, AE adverse events, PLR primary lack of response, SLR secondary lack of response
Other refers to reason of discontinuation other than lack of effect or intolerance. Response/tolerance refers to proportion of patients with a valid follow-up achieving the
respective response criterion (with patients having discontinued treatment being defined as nonresponders). Per protocol refers to proportion of patients achieving the
respective response criterion among those patients still receiving treatment
Except where indicated otherwise, values are percentages
ap Value overall
bp Value PLR vs. SLR
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Over 75 % of the patients in the SCQM Cohort met the
ASAS classification criteria for axSpA. Patients fulfilling
the ASAS criteria showed comparable response rates
(with 19 %, 38 %, and 55 % reaching an ASDAS-ESR <2.1
in the PLR, AE, and SLR groups, respectively) to those of
the patients in the entire cohort defined by the treating
rheumatologists.
A limitation of our response analyses is that follow-up
data of ASDAS at 12 months was available for only ap-
proximately one-third of patients. However, patients
with versus without follow-up at this time point did not
differ with regard to clinically relevant baseline disease
characteristics. The limitation of incomplete follow-up is
inherent to observational registries. In the NOR-
DMARD registry [18], ASDAS responses were available
in 25 % of patients at 3 months and 29 % at the last ob-
servation and in DANBIO in 45 % of patients at 2 years
[22]. There was no difference in response rates among
the various anti-TNF agents used as second-line treat-
ment in DANBIO, while drug survival of second treat-
ment courses was longer in adalimumab-treated patients
previously treated with infliximab [22]. In RA, drug sur-
vival of infliximab was shown to be inferior to adalimu-
mab or etanercept [26], although other comparisons
yielded a similar maintenance of various TNFi [42].
Moreover, the type of TNFi switch was shown to affect
the effectiveness of a second TNFi in RA: Switching
from an anti-TNF mAb to a soluble TNF receptor
yielded better results than vice versa [26]. We were un-
able to confirm differences between individual anti-TNF
agents or between various types of switching with regard
to drug maintenance.
Conclusions
Our findings suggest that the effectiveness of a second
TNFi is impaired in patients with axSpA who have expe-
rienced a PLR to a first TNFi during the first 6 months
of treatment.
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